Biopharmaceutical drug pricing and market access contracting has become more complicated and interrelated than ever. The profitability of both pricing decisions and contracting decisions are now firmly linked and a quickly evolving legislative and regulatory shift in the area of state price transparency reporting is further elevating the compliance implications of adjustments in price. Finally, the march from volume-based to value-based commercial models demands the linkage of outcomes and real world data to be linked into this broader solution footprint.

Learn about a more integrated and intuitive approach to linking pricing, contracting, and value-based decisions to create organizational agility and an ability to scale in this quickly changing complex landscape. Discover how this inter-connected approach can have a radical impact on the profitability of life sciences organizations as well as align incentives across the health care ecosystems.
https://deloi.tt/3nYuWFz
------
Subscribe to Deloitte US: https://www.youtube.com/user/DeloitteLLP?sub_confirmation=1

Connect with us on social:
LinkedIn: https://www.linkedin.com/company/deloitte
Facebook: https://www.facebook.com/deloitte/
Twitter: https://twitter.com/deloitteus
Instagram: https://www.instagram.com/deloitte/?hl=en

Visit Deloitte.com: https://deloi.tt/2IM5HBF